Acrivon Therapeutics, Inc.

Analysis for Ticker: ACRV

Acrivon Therapeutics Inc is a precision oncology business that uses a platform called AP3 to analyze protein signaling in tumors to find patients who might respond to its experimental drugs. The clinical reality is a financial incinerator that has amassed an accumulated deficit of 274,9$ million without ever selling a single product. This company operates as a wealth transfer machine where the public provides cash to fund a clinical trial while the insiders use that same equity to pay their personal tax bills. It is like a group of people asking you to fund a lemonade stand that has no lemons and no customers, but they keep taking some of your money to pay for their own chores at home. The mechanism of extraction was established through licensing deals and service agreements. Acrivon handed over a 5,0$ million upfront fee to Eli Lilly for its lead drug and agreed to pay up to 168,0$ million in future milestones plus royalties up to 10%. They also let Akoya Biosciences siphon 18,2$ million to develop diagnostic tests. By 04/2024, the treasury was low, so they printed 8.235.000 new shares and 7.060.000 warrants to extract 123,8$ million from the public. This dilution mathematically shrank the ownership of every original investor.